- Home
- BCDA vs ADN Comparison
BCDA vs ADN Comparison
Compare BCDA & ADN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ADN
- Stock Information
- Founded
- BCDA N/A
- ADN 2006
- Country
- BCDA United States
- ADN United States
- Employees
- BCDA N/A
- ADN N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ADN Power Generation
- Sector
- BCDA Health Care
- ADN Utilities
- Exchange
- BCDA Nasdaq
- ADN Nasdaq
- Market Cap
- BCDA 9.4M
- ADN 7.5M
- IPO Year
- BCDA N/A
- ADN N/A
- Fundamental
- Price
- BCDA $1.92
- ADN $2.10
- Analyst Decision
- BCDA Strong Buy
- ADN
- Analyst Count
- BCDA 1
- ADN 0
- Target Price
- BCDA $25.00
- ADN N/A
- AVG Volume (30 Days)
- BCDA 93.6K
- ADN 21.2K
- Earning Date
- BCDA 05-13-2025
- ADN 12-27-2024
- Dividend Yield
- BCDA N/A
- ADN N/A
- EPS Growth
- BCDA N/A
- ADN N/A
- EPS
- BCDA N/A
- ADN N/A
- Revenue
- BCDA $58,000.00
- ADN $8,157,000.00
- Revenue This Year
- BCDA N/A
- ADN $2,232.99
- Revenue Next Year
- BCDA N/A
- ADN $91.56
- P/E Ratio
- BCDA N/A
- ADN N/A
- Revenue Growth
- BCDA N/A
- ADN 274.35
- 52 Week Low
- BCDA $1.63
- ADN $1.71
- 52 Week High
- BCDA $6.15
- ADN $8.79
- Technical
- Relative Strength Index (RSI)
- BCDA 38.14
- ADN 22.88
- Support Level
- BCDA $1.73
- ADN $2.49
- Resistance Level
- BCDA $1.93
- ADN $2.84
- Average True Range (ATR)
- BCDA 0.13
- ADN 0.32
- MACD
- BCDA -0.01
- ADN -0.07
- Stochastic Oscillator
- BCDA 30.95
- ADN 0.00
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.